SPORANOX ORAL SOLUTION Rx
Generic Name and Formulations:
Itraconazole 10mg/mL; cherry-caramel flavor.
Janssen Pharmaceuticals, Inc.
Indications for SPORANOX ORAL SOLUTION:
Oropharyngeal and esophageal candidiasis (not recommended for initiation of treatment if immediate risk of systemic candidiasis).
Caps and soln are not interchangeable. Take on empty stomach. Swish and swallow 10mL at a time. Oropharyngeal: 200mg (20mL) daily for 1–2 weeks; fluconazole-resistant: 100mg (10mL) twice daily. Esophageal: 100mg daily; doses up to 200mg/day may be used. Treat for at least 3 weeks, continue 2 weeks after symptoms resolve.
Treatment of onychomycosis in CHF, pregnancy, or contemplating pregnancy. Concomitant methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergots, irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor. Concomitant colchicine, fesoterodine, or solifenacin in renal/hepatic impairment. Concomitant eliglustat in poor or intermediate CYP2D6 metabolizers or those taking strong or moderate CYP2D6 inhibitors.
Congestive heart failure. Cardiac effects and drug interactions.
Not for treatment of onychomycosis in patients with ventricular dysfunction (eg, CHF). CHF risk (eg, ischemic/valvular disease, COPD, renal failure, edema); monitor and discontinue if occurs. Monitor for signs/symptoms of liver dysfunction; discontinue and perform LFTs if develop. Reduced gastric acidity, achlorhydria (eg, in HIV): reduced capsule bioavailability; cola drink has shown to increase absorption. Discontinue if neuropathy or hearing loss occurs. Immunocompromised: adjust dose based on clinical response. Cystic fibrosis: switch to alternative therapy if no response. Renal impairment. Elderly. Pregnancy (Cat.C): use effective contraception during and for 2 months after therapy. Nursing mothers: not recommended.
See Contraindications. Serious cardiac effects with cisapride, pimozide, methadone, quinidine, others. Concomitant alfuzosin, silodosin, tamsulosin, fentanyl, apixaban, rivaroxaban, vorapaxar, antineoplastics (see full labeling), simeprevir, aliskiren, riociguat, sildenafil or tadalafil (for PAH), everolimus, sirolimus, IV temsirolimus, salmeterol, darifenacin, vardenafil, colchicine, conivaptan, tolvaptan, regorafenib, saccharomyces boulardii: not recommended during and 2 weeks after itraconazole. Avoid itraconazole for more than 2 weeks during bedaquiline therapy. Rifabutin, carbamazepine, lumacaftor/ivacaftor: avoid 2 weeks before, during, and 2 weeks after itraconazole. Avoid isoniazid, rifampicin, phenobarbital, phenytoin, efavirenz, nevirapine 2 weeks before and during itraconazole therapy. Potentiates alfentanil, buprenorphine, oxycodone, sufentanil, digoxin, clarithromycin, trimetrexate, cilostazol, dabigatran, warfarin, repaglinide, saxagliptin, praziquantel, eletriptan, antineoplastics (see full labeling), antipsychotics, anxiolytics, hypnotics, zopiclone, daclatasvir, indinavir, maraviroc, nadolol, diltiazem, other dihydropyridines, verapamil, bosentan, guanfacine, aprepitant, loperamide, netupitant, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, cyclosporine, tacrolimus, atorvastatin, venlafaxine, fesoterodine, solifenacin, dutasteride, oxybutynin, sildenafil, tadalafil, tolterodine, eliglustat, oral alitretinoin, cabergoline, cannabinoids, cinacalcet, ivacaftor; monitor, may need to reduce dose of these. Concomitant artemether-lumefantrine, quinine, cobicistat, elvitegravir (ritonavir-boosted), ritonavir, saquinavir (unboosted), tenofovir disoproxil fumarate, dienogest, ulipristal; monitor for adverse events. Antagonizes meloxicam; increase dose if necessary. Potentiated by ciprofloxacin, erythromycin, clarithromycin, idelalisib, cobicistat, protease inhibitors, diltiazem, other CYP3A4 inhibitors; monitor, may need to reduce itraconazole dose. Give gastric acid suppressants (eg, antacids, H2 blockers, PPIs) at least 2hrs before or 2hrs after itraconazole caps. Tinnitus or hearing impairment with quinidine. Increased risk of CHF with concomitant CCBs.
Nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, upper respiratory symptoms, pruritus; hepatotoxicity (may be serious), CHF, neuropathy, hearing loss.
Caps—30; Caps PulsePak—28; Oral soln—150mL
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Methadone Improves Short-Term Outcomes Better Than Morphine in Neonatal Abstinence Syndrome
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Hospital-Owned Practices Associated With Positive Workplace Perceptions Among Staff
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Chinese Traditional Medicine Showed Effectiveness on Pain, Quality of Life in Advanced Cancer